Azenta to Participate in 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

8/5/24 4:05:00 PM ET

Industrial Machinery/Components

Technology

Get the next $AZTA alert in real time by email

BURLINGTON, Mass., Aug. 5, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, on Monday, August 12, 2024.

About Azenta Life Sciences

Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey and B Medical Systems.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

INVESTOR CONTACTS:

Yvonne Perron

Vice President, Financial, Planning & Analysis and Investor Relations

[email protected]

Sherry Dinsmore

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-to-participate-in-9th-annual-needham-virtual-medtech--diagnostics-1x1-conference-302214700.html

SOURCE Azenta

Get the next $AZTA alert in real time by email

Recent Analyst Ratings for

$AZTA

Date	Price Target	Rating	Analyst
4/4/2024	$64.00	Hold	Jefferies
2/1/2024	$61.00 → $79.00	Buy	B. Riley Securities
7/19/2023		Mkt Perform	Raymond James
5/10/2023		Overweight → Sector Weight	KeyBanc Capital Markets
2/9/2023	$65.00 → $60.00	Overweight → Equal-Weight	Stephens
1/3/2023	$60.00 → $62.00	Outperform → In-line	Evercore ISI
3/31/2022	$106.00	Buy	B. Riley Securities
3/21/2022	$100.00	Outperform	Evercore ISI

More analyst ratings

Azenta to Participate in 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Chat with this insight

Recent Analyst Ratings for $AZTA

$AZTA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jefferies initiated coverage on Azenta with a new price target

B. Riley Securities reiterated coverage on Azenta with a new price target

Raymond James initiated coverage on Azenta

$AZTA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP and CHRO Pirogova Olga sold $21,958 worth of Common (548 units at $40.07), decreasing direct ownership by 3% to 19,373 units (SEC Form 4)

SVP, General Counsel, Secy. Joseph Jason sold $45,640 worth of Common (1,139 units at $40.07), decreasing direct ownership by 1% to 112,564 units (SEC Form 4)

SVP and General Manager, Genom Zhou Ginger sold $19,674 worth of Common (491 units at $40.07), decreasing direct ownership by 2% to 27,499 units (SEC Form 4)

$AZTA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

President and CEO Marotta John was granted 83,622 units of Common and bought $552,904 worth of Common (13,967 units at $39.59), increasing direct ownership by 2,982% to 100,862 units (SEC Form 4)

Director Cornog William L bought $495,000 worth of Common (12,500 units at $39.60) (SEC Form 4)

Director Hirsch Didier bought $39,500 worth of Common (1,000 units at $39.50), increasing direct ownership by 41% to 3,465 units (SEC Form 4)

$AZTA Market Insights

Live Market Insights

Azenta To Provide Proteomics Technology For FinnGen Project, Profiling Up To 20,000 Individuals; Project Analyzes Genomic And Health Data From 500,000 Finnish Biobank Participants

Decoding 5 Analyst Evaluations For Azenta

Evercore ISI Group Maintains In-Line on Azenta, Raises Price Target to $53

$AZTA Financials

Live finance-specific insights

Azenta Reports Fourth Quarter and Full Year Fiscal 2024 Results; Announces the Plan to Sell B Medical Systems and Appoints Lawrence Y. Lin as CFO

Azenta Announces Fiscal 2024 Fourth Quarter and Full Year Earnings Conference Call and Webcast

Azenta Reports Third Quarter Results for Fiscal 2024, Ended June 30, 2024

$AZTA Press Releases

Fastest customizable press release news feed in the world

Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

Azenta to Participate in Stephens Annual Investment Conference

Azenta Reports Fourth Quarter and Full Year Fiscal 2024 Results; Announces the Plan to Sell B Medical Systems and Appoints Lawrence Y. Lin as CFO

$AZTA SEC Filings

Azenta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

Azenta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

Azenta Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

$AZTA Leadership Updates

Live Leadership Updates

Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

$AZTA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Azenta Inc.

Amendment: SEC Form SC 13D/A filed by Azenta Inc.

SEC Form SC 13G filed by Azenta Inc.

Recent Analyst Ratings for
$AZTA

$AZTA
Analyst Ratings

$AZTA
Insider Trading

$AZTA
Insider Purchases

$AZTA
Market Insights

$AZTA
Financials

$AZTA
Press Releases

$AZTA
SEC Filings

$AZTA
Leadership Updates

$AZTA
Large Ownership Changes